Locally advanced basal cell carcinoma in real life: Analysis of a cohort of 452 patients treated with systemic therapy from the CARADERM database by F. Herms, M. Djermane, M. Beylot-Barry, C. Chaffaut, S. Dalac, O. Dereure, J.J. Grob, L. Mortier, J. Lambert, N. Basset-Seguin

Get full text

Impact of thyroid immune-related adverse events on clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with checkpoint inhibitor therapy: A single center study by Šejla Cerić, Timur Cerić, Emir Sokolović, Jasmina Dalač, Dragana Miletić, Inga Marijanović, Layan Mattar, Amina Aljić, Selma Agić-Bilalagić, Amera Šadija, Miran Hadžiahmetović, Semir Bešlija

Get full text

BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis by Antoine Toubert, Eric Pasmant, Alexandra Frazao, Louise Rethacker, Géraldine Jeudy, Marina Colombo, Marie-Françoise Avril, Helene Moins-Teisserenc, Marie Roelens, Sophie Dalac, Eve Maubec, Anne Caignard

Get full text

Updated outcomes of AdjuMel study: real-world data in patients with resected stage III-IV melanoma treated with adjuvant nivolumab in France by S. Dalle, P. Saiag, C. Lebbé, J.-J. Grob, B. Dréno, S. Dalac, B. Asselain, F. Skowron, S. Darras, N. Jovenin, G. Quereux, A. Khammari, C. Rieuf, F. Brellier, S. Houssou, L. Mortier

Get full text